Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Northside Capital Management LLC

Northside Capital Management LLC lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 144.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,226 shares of the medical equipment provider’s stock after purchasing an additional 82,844 shares during the period. Northside Capital Management LLC owned about 0.07% of Zimmer Biomet worth $12,609,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Zimmer Biomet by 0.9% during the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock worth $2,120,751,000 after buying an additional 198,370 shares in the last quarter. Dodge & Cox increased its holdings in shares of Zimmer Biomet by 5.1% in the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock valued at $2,286,793,000 after buying an additional 1,118,710 shares in the last quarter. Capital International Investors increased its holdings in shares of Zimmer Biomet by 11.5% in the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after buying an additional 778,467 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Zimmer Biomet by 8.7% during the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after acquiring an additional 458,903 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Zimmer Biomet by 15.2% during the 2nd quarter. Franklin Resources Inc. now owns 4,673,860 shares of the medical equipment provider’s stock worth $426,303,000 after acquiring an additional 615,014 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ZBH shares. Sanford C. Bernstein lifted their target price on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a report on Friday, January 9th. Wells Fargo & Company increased their price target on Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. UBS Group restated a “sell” rating and set a $89.00 price objective on shares of Zimmer Biomet in a report on Wednesday, February 11th. Finally, William Blair initiated coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They set a “market perform” rating for the company. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Price Performance

ZBH opened at $88.04 on Friday. The firm has a market capitalization of $17.23 billion, a P/E ratio of 24.87, a PEG ratio of 1.79 and a beta of 0.58. The stock has a fifty day moving average of $92.12 and a 200-day moving average of $94.66. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. Zimmer Biomet Holdings, Inc. has a 12-month low of $84.59 and a 12-month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. The business had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.Zimmer Biomet’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is 27.12%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.39% of the stock is owned by corporate insiders.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.